ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorSuzhou Zelgen Biopharmaceuticals Co.,Ltd
About this trial
This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.
Eligibility criteria
Qualifiers
Fully understand the study and voluntarily sign the informed consent form.
Male or female 18-70 years of age.
Participants with advanced small cell lung cancer or neuroendocrine carcinoma confirmed by histopathology or cytology.
Eastern Cooperative Oncology Group (ECOG) 0 to 1.
Disqualifiers
The investigator believes that the subject has other reasons that make them unsuitable for participation in this study.
Trial design
Treatments tested in this trial
- ZG006
- ZG005
Treatment groups
350 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov